Morgan Stanley initiated coverage of Cidara Therapeutics (CDTX) with an Overweight rating and $190 price target The company’s CD388 demonstrated meaningful flu prevention in a Phase 2 trial and is well positioned as a complement to vaccines, the analyst tells investors in a research note. The firm says that with Phase 3 interim data expected in June of 2026, it sees “broad protection and season-long durability as key differentiator” for the drug.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDTX:
- Buy Rating for Cidara Therapeutics: Promising Antiviral CD388 Targets $5 Billion Influenza Market
- Align downgraded, NetEase upgraded: Wall Street’s top analyst calls
- Cidara Therapeutics initiated with an Overweight at JPMorgan
- Cidara Therapeutics: Strategic Advancements and Financial Strength Bolster Buy Rating
- Cidara Therapeutics price target raised to $150 from $110 at H.C. Wainwright